DocWire News with spoke with Mike Clayman, MD, CEO at Flexion Therapeutics, a company focused on the development of novel, local therapies for the treatment of musculoskeletal (MSK) conditions – with one approved drug – ZILRETTA® for osteoarthritis (OA) knee pain. See what Dr. Clayman had to say about these therapies.
Patients with mild radiographic OA of the knee who use non-steroidal anti-inflammatory drugs (NSAIDs) and do not meet physical activity guidelines are at risk of radiographic progression, according to a study. Overall, 58 patients (12%) sustained radiographic OA progression. Univariate analysis identified NSAID use, inadequate physical activity, and high baseline pain as clinical factors eligible for inclusion in the multivariable model.
A study observed a correlation between patients’ expectations toward newly induced disease-modifying antirheumatic drug therapies and clinical response among patients with rheumatoid arthritis.
Finally, a review published in RMD Open discussed the literature currently available regarding intra-articular therapies (IAT) for autoimmune and rheumatic diseases.
In Case You Missed It: